|Day's Range||284.30 - 284.30|
|52 Week Range||138.01 - 286.30|
|PE Ratio (TTM)||43.72|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
U.S. healthcare giant Johnson & Johnson has offered concessions in a bid to address EU antitrust concerns over its $30 billion bid for Swiss biotech company Actelion, the European Commission said on Thursday. Johnson & Johnson put in the offer on Wednesday. The deal, the biggest in the European pharmaceutical industry in 13 years, would give J&J access to Actelion's range of high-price, high-margin medicines for rare diseases, helping it diversify its drug portfolio as its biggest product, Remicade for arthritis, faces cheaper competition.
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Actelion Ltd. a score of 75. Our analysis is based on comparing Actelion Ltd. with the following peers – Medicines Company, Ionis Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc. and Novavax, Inc. (MDCO-US, IONS-US, REGN-US and NVAX-US). Investment Outlook Actelion Ltd. has a fundamental score of 75 and has ... Read more (Read more...)
Categories: ETFs Yahoo FinanceClick here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Actelion Ltd.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average ... Read more (Read more...)